Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from SSY Group ( (HK:2005) ).
SSY Group Limited has secured approval from China’s National Medical Products Administration for the production and registration of its Propafenone Hydrochloride Injection (20ml:70mg), classified as a type 3 chemical drug and deemed to have passed consistency evaluation, marking the third such approval granted to entities in the mainland market. The newly approved injection, indicated for the treatment of various supraventricular and ventricular tachyarrhythmias including WPW syndrome and paroxysmal atrial fibrillation, broadens SSY Group’s cardiovascular treatment portfolio and underscores its progress in high‑value injectable drugs, potentially strengthening its competitive position in China’s hospital drug market and enhancing growth prospects for shareholders and investors.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a Hong Kong-listed pharmaceutical group engaged in the development, production and sale of drug products, with a focus on injectable formulations for the Chinese healthcare market. The company operates through subsidiaries in mainland China and targets hospital and clinical demand for specialized treatments.
Average Trading Volume: 5,462,934
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.74B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.